Barclays lowered the firm’s price target on Tandem Diabetes (TNDM) to $53 from $60 and keeps an Overweight rating on the shares. The company reported mixed results and in-line guidance, but nothing likely justifies the 30% drop in the stock, the analyst tells investors in a research note. The firm believes Tandem’s “strong pipeline and beatable outlook” position the stock go higher.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- Tandem Diabetes Care: Record Sales and Strategic Growth
- Tandem Diabetes price target lowered to $55 from $65 at RBC Capital
- Tandem Diabetes price target lowered to $33 from $37 at Baird
- Sell Rating for Tandem Diabetes Care Due to Revenue Shortfalls and High Valuation
- Tandem Diabetes price target lowered to $58 from $63 at Canaccord